Last reviewed · How we verify
SDD Gastric Suspension
SDD Gastric Suspension selectively decontaminates the stomach by delivering antimicrobial agents to reduce pathogenic bacteria while preserving beneficial flora.
SDD Gastric Suspension selectively decontaminates the stomach by delivering antimicrobial agents to reduce pathogenic bacteria while preserving beneficial flora. Used for Prevention of infections in critically ill patients (Phase 3 development).
At a glance
| Generic name | SDD Gastric Suspension |
|---|---|
| Also known as | Colistin, Tobramycin and Nystatin |
| Sponsor | The George Institute |
| Drug class | Selective decontamination agent |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Infection Prevention |
| Phase | Phase 3 |
Mechanism of action
Selective decontamination of the digestive tract (SDD) is a strategy to prevent infections in critically ill patients by reducing gram-negative aerobic bacteria and fungi in the gastrointestinal tract. The gastric suspension formulation targets the stomach specifically, aiming to lower infection rates and improve clinical outcomes in high-risk populations without causing systemic antibiotic resistance.
Approved indications
- Prevention of infections in critically ill patients (Phase 3 development)
Common side effects
- Gastrointestinal tolerance issues
- Taste disturbance
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SDD Gastric Suspension CI brief — competitive landscape report
- SDD Gastric Suspension updates RSS · CI watch RSS
- The George Institute portfolio CI